Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition

Longeveron said its experimental stem cell therapy failed to meet the primary endpoint in a mid-stage trial for a rare infant heart condition. The company will explore strategic options following the clinical setback, increasing uncertainty around its pipeline and corporate future.